Auch wir verwenden Cookies. Mehr Informationen in der Datenschutzerklärung

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

FibroGen Appoints Enrique Conterno as Its New CEO

TheMotleyFool

0 0

FibroGen Appoints Enrique Conterno as Its New CEOPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

FibroGen (NASDAQ: FGEN), a biotech that was founded to focus on fibrosis, but has expanded into other disease mechanisms, appointed Enrique Conterno as its new CEO on Monday. Shares of FibroGen were trading flat on the news at 12:32 p.m. EST.

Conterno replaces Jim Schoeneck, who served as the company's interim CEO since August 2019 after founder and longtime CEO Tom Neff died unexpectedly. Schoeneck will become the chairman of the board of directors.

Conterno was most recently the president of Eli Lilly's (NYSE: LLY) Lilly USA and Lilly diabetes divisions, having retired at the end of 2019, following 27 years working at Eli Lilly.

Source Fool.com

Like: 0

FGEN

Teilen